All articles by Annabel Kartal Allen

Annabel Kartal Allen

Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel

Clariyon’s AI tool boosts sepsis care compliance in hospital study

Clariyon’s artificial intelligence (AI)-powered sepsis care agent has shown potential in improving a physician’s ability to provide quality care to…
Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy

Absci Corporation has secured $100m in an underwritten offering while reporting positive first-in-human (FIH) data for its lead candidate ABS-201,…
UK bookmarks Spain’s success in race to global clinical trials competitiveness

In recent years, the UK clinical trials sector has faced stiff competition as it looks to build a strong global…
Analysts point to Definium psychedelic’s MDD efficacy on Phase III success

Following the first late-stage win in a Phase III programme evaluating Definium Therapeutics’ lysergic acid diethylamide (LSD)-based psychedelic in major…
HLTH Europe 2026: incorporating RWE into practice – the perks and pitfalls

As the life sciences sector rapidly progresses into the digital age, several tools are emerging with the potential to revolutionise…

Podcast: AI in oncology – the trials, tribulations and opportunities

In recent years, artificial intelligence (AI) has become one of the largest talking points within the pharma space – a…
Podcast: Championing the next generation of life sciences talent, a NIHR perspective

With so much innovation happening within the life sciences sector, now is arguably the perfect time for new faces to…
Novartis $12bn bet on Avidity well placed after mid-stage FSHD win

Novartis’ $12bn Avidity Biosciences buyout is looking increasingly well positioned, as one of the latter company’s lead assets, delpacibart braxlosiran…
ADA26: key obesity readouts from the conference

As the 2026 American Diabetes Association (ADA) conference draws to a close for another year, Clinical Trials Arena gives you…
Innovent eyes third-line nod for gastric cancer ADC on Phase III PFS hit

Takeda’s $11.4bn bet on assets from Chinese biotech, Innovent Biologics, is showing early signs of paying off, as the latter…